• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology

Quote




































Pipeline is a joke and the markets we are tying to break into, Endo, MF, MDS have plenty of better and less toxic options than Seli or El. With revenue being low and already flattering, a cash burn that will not last 12 months(despite what lies RP is telling), and a very green executive team this is a recipe for disaster.
 












It's over. If any 'big pharma' believed in Seli or our...emm, cough, 'pipeline', they could buy us on the cheap right now. No way we would turn down $10 a share, especially in light of CTI's buyout. That's the going rate from a market cap perspective for companies with similar revenue drugs and pipelines.

If we truly have no suitors, it tells us all we need to know about how other business development departments view our assets. There is a reason no one is buying us...what makes us think that we have it right and the rest of the world has it wrong?

We haven't been right yet.
 
































Top Bottom
Back
Quote